Connect with us

Technology

Waisman Biomanufacturing and RoosterBio Announce Collaboration for GMP Manufacturing of Cell and Exosome Therapies

Published

on

Through this collaboration, Waisman Biomanufacturing will incorporate RoosterBio’s cutting-edge MSC and exosome bioprocessing products, manufacturing protocols, and analytical services into its portfolio.

FREDERICK, Md., Feb. 13, 2024 /PRNewswire-PRWeb/ — Waisman Biomanufacturing, a leading contract development and manufacturing organization (CDMO) which is strategically part of the University of Wisconsin Madison, announced today a strategic partnership with RoosterBio, Inc., a leading provider of human mesenchymal stem/stromal cells (MSCs), highly engineered media solutions, and bioprocess development services.

“Waisman Biomanufacturing occupies a unique and critically important niche in the biologics CDMO landscape.” – Tim Kelly, CEO, RoosterBio

Through this collaboration, Waisman Biomanufacturing will incorporate RoosterBio’s cutting-edge MSC and exosome bioprocessing products, manufacturing protocols, and analytical services into its portfolio of biologics manufacturing services, expanding Waisman Biomanufacturing’s capabilities for the production of advanced therapies for clinical trials.

Together, Waisman Biomanufacturing and RoosterBio deliver an end-to-end solution for the development and manufacturing of cell- and exosome-based therapeutics, including the critical raw materials, expert process development in both 2D and 3D systems, advanced analytical characterization, regulatory support packages, and proven cGMP manufacturing capabilities. Advanced therapy developers in both industry and academia can now accelerate and de-risk their progression into clinical trials by leveraging this new strategic collaboration.

Christopher Bartley, Managing Director of Waisman Biomanufacturing, expressed his excitement for this collaboration: “Waisman Biomanufacturing focuses on partnerships and collaboration, valuing its ability to move products into clinical trials as quickly and effectively as possible. I truly appreciate that our values and mission align well with RoosterBio’s with the ultimate purpose to address unmet needs. We are thrilled to partner with RoosterBio in the pursuit of excellence toward that goal.”

“Waisman Biomanufacturing occupies a unique and critically important niche in the biologics CDMO landscape,” said Tim Kelly, Chief Executive Officer of RoosterBio. “For over 20 years, Waisman has built a track record of success in clinical manufacturing of biologics for a broad range of clients in emerging biopharma and institutional settings, where much of the innovation in advanced therapy development resides. I am very excited to partner with Waisman to provide scalable manufacturing solutions to our clients and deliver highly impactful advanced therapies to patients everywhere.”

About RoosterBio

RoosterBio accelerates human mesenchymal stem/stromal cell (hMSC) and extracellular vesicle (EV) product and process development to fuel the rapid implementation of scalable advanced therapies. Our high-quality hMSCs, bioprocess media, genetic engineering tools, and EV production solutions are paired with expert bioprocessing knowledge to progress therapeutic developers from concept to first-in-human testing and commercial manufacturing at reduced cost and increased productivity. With optimized, scalable processes, Type 2 Master Files, and cGMP products, we have enabled therapeutic programs to traverse their path to clinical translation in under 1 year. RoosterBio is driven by clients’ success and creating a world where safe and effective regenerative medicines are rapidly developed and widely available on a global scale.

About Waisman Biomanufacturing
With its state-of-art production facility in Madison, WI, and its expert personnel, Waisman Biomanufacturing has become a leading GMP contract manufacturing organization (CMO) which manufactures a wide range of biotherapeutics for clinical trials. The products include gene therapies, cell therapeutics, and both therapeutic and prophylactic vaccines. More information is available at: gmpbio.org.

Media Contact

Kim Hastings, RoosterBio, Inc., 301-200-5366, info@roosterbio.com

View original content:https://www.prweb.com/releases/waisman-biomanufacturing-and-roosterbio-announce-collaboration-for-gmp-manufacturing-of-cell-and-exosome-therapies-302060339.html

SOURCE RoosterBio, Inc.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Hexagon Interim Report 1 January – 31 March 2026

Published

on

By

STOCKHOLM, April 23, 2026 /PRNewswire/ —

First quarter 2026

Continuing operations

Operating net sales of 963.8 (961.5) resulting in organic growth of 8%Net sales including acquired deferred revenue amounted to 963.6 MEUR (961.5)Adjusted gross earnings of 606.3 (619.1) resulting in a 62.9% (64.4) gross marginAdjusted operating earnings (EBIT1) of 251.3 MEUR (248.7) resulting in a 26.1% (25.9) EBIT1 marginAdjusted earnings per share of 6.7 Euro cent (6.5)Earnings per share of 58.4 Euro cent (5.0)Cash conversion of 77% (60)Recurring revenue of 289.9 MEUR (308.0), 6% organic growthOctave reported operating net sales of 327.2 MEUR (361.3) and adjusted operating margin of 25.2% (26.6)Adjusted earnings per share including discontinued operations of 9.1 (9.4)Earnings per share including discontinued operations of 59.9 Euro cent (7.0)

For further information, please contact:
Tom Hull, Head of Investor Relations, +44 (0) 7442 678 437, ir@hexagon.com
Anton Heikenström, Investor Relations Manager, +46 8 601 26 26, ir@hexagon.com

This is information that Hexagon AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08:00 CET on 23 April 2026.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/hexagon/r/hexagon-interim-report-1-january—31-march-2026,c4338783

The following files are available for download:

 

View original content:https://www.prnewswire.com/news-releases/hexagon-interim-report-1-january—31-march-2026-302751432.html

SOURCE Hexagon

Continue Reading

Technology

Dragonpass Empowers Financial Institutions with End-to-End Loyalty Solutions at Money20/20 Asia

Published

on

By

BANGKOK, April 23, 2026 /PRNewswire/ — Dragonpass, a leading global travel and lifestyle platform, participated in Money20/20 Asia, showcasing its customer loyalty solutions for banks, payment providers, credit card issuers, and fintech companies across APAC and globally.

As one of the most influential fintech events worldwide, Money20/20 Asia gathers decision-makers across the financial ecosystem. At the event, Dragonpass demonstrated how financial institutions can enhance customer engagement and build long-term loyalty through integrated travel and lifestyle experiences.

Established in 2005, Dragonpass has evolved from a lounge provider into a loyalty solutions partner, serving more than 800 global clients and over 40 million members worldwide.

At the core of Dragonpass is a business structure that combines global supply aggregation, a technology-enabled engagement platform, and consumer-facing lifestyle services — providing a one-stop solution across the customer lifecycle.

Leveraging data-driven insights, Dragonpass enables partners to design and optimise loyalty programs, incorporating customer segmentation and tiered incentive structures, alongside curated campaigns and entitlement configuration — driving more effective customer activation, engagement, and retention.

Its offering includes a broad portfolio of travel and lifestyle benefits such as airport lounge access, fast-track, dining, airport transfers, and lifestyle experiences. These are supported by flexible delivery models, including API integration, white-label solutions, and ready-to-deploy digital platforms, enabling seamless integration into clients’ customer journeys.

As customer expectations evolve, the industry is shifting from standardized benefits to more personalized, experience-led loyalty models. Insights from Dragonpass’s Loyalty Index show that customers increasingly value trust, rewards, simplicity, recognition, and exclusivity, with preferences varying across markets.

“Financial institutions today are looking for more effective ways to engage customers beyond traditional rewards,” said Jane Zhu, Co-founder and CEO of Dragonpass. “User engagement is at the core of loyalty, and technology — especially AI — plays a key role in enabling deeper and more relevant customer connections.”

Dragonpass works with leading global brands including Mastercard, Visa, HSBC, and Revolut, supporting them deliver differentiated value propositions and enhance customer engagement through scalable, customizable solutions.

Through its participation at Money20/20 Asia, Dragonpass aims to strengthen its presence in the APAC market and build strategic partnerships with organizations seeking to elevate their customer engagement strategies.

About Dragonpass

Dragonpass is a global travel and lifestyle platform providing premium airport and travel experiences across 140+ countries. By integrating global supply and technology, Dragonpass enables partners to deliver seamless, personalized experiences and drive customer loyalty.

Media Contact

Dragonpass PR
Email: brandmarketing@dragonpass.com
Website: www.dragonpass.com

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/dragonpass-empowers-financial-institutions-with-end-to-end-loyalty-solutions-at-money2020-asia-302751442.html

SOURCE Dragonpass

Continue Reading

Technology

SBI Life Insurance registers New Business Premium of ₹42,551 crores for the year ended on 31st March, 2026

Published

on

By

MUMBAI, India, April 23, 2026 /PRNewswire/ — SBI Life Insurance, one of the leading life insurers in the country registered a New Business Premium of ₹42,551 crores for the year ended on 31st March, 2026 vis-a-vis ₹35,577 crores for the year ended 31st March, 2025. Single premium has increased by 28% over the year ended on 31st March, 2025.

Establishing a clear focus on protection, SBI Life’s protection new business premium stood at ₹4,622 crores for the year ended 31st March, 2026, marking a growth of 13%. Protection Individual new business premium registered a growth of 23% and stood at ₹973 crores for the year ended 31st March, 2026. Individual New Business Premium stands at ₹29,783 crores with 13% growth over the year ended on 31st March, 2025.

SBI Life’s profit after tax stands at ₹2,470 crores for the year ended 31st March, 2026 with a growth of 2% over the year ended on 31st March, 2025.

The company’s solvency ratio continues to remain robust at 1.90 as on 31st March, 2026 as against the regulatory requirement of 1.50.

SBI Life’s AUM also continued to grow at 9% to ₹4,87,163 crores as on 31st March, 2026 from ₹4,48,039 crores as on 31st March, 2025, with the debt-equity mix of 62:38. 94% of the debt investments are in AAA and Sovereign instruments.

The company has a diversified distribution network of 3,58,506 trained insurance professionals and wide presence with 1,230 offices across the country, comprising of strong bancassurance channel, agency channel and others comprising of corporate agents, brokers, Point of Sale Persons (POS), insurance marketing firms, web aggregators and direct business.

Performance for the year ended March 31, 2026

Private Market leadership in Individual New Business Premium and Individual Rated Premium with market share of 25.5% & 22.9% respectively.Annualized Premium Equivalent (APE) stands at ₹ 24,266 crores with growth of 13%Individual New Business Sum Assured stands at ₹ 4,46,337 crores with 61% growthImprovement in 13M & 49M persistency by 53 bps & 107 bps respectivelyValue of New Business (VoNB) stands at ₹ 6,667 crores with growth of 12%VoNB Margin stands at 27.5%Indian Embedded value (IEV) stands at ₹ 80,791 crores with 15% growthProfit After Tax (PAT) stands at ₹ 2,470 crores with 2% growthOperating Return on Embedded Value stands at 19.7% Assets under Management stands at ₹ 4,87,163 crores with 9% growthRobust Solvency ratio of 1.90

Logo: https://mma.prnewswire.com/media/2672544/SBI_Life_25_Years_Logo.jpg

 

View original content:https://www.prnewswire.com/in/news-releases/sbi-life-insurance-registers-new-business-premium-of-42-551-crores-for-the-year-ended-on-31st-march-2026–302751447.html

Continue Reading

Trending